Display options
Cite
Alvarez E, Malogolowkin M, Pollock BH, et al. Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma-A population-based study. Pediatr Blood Cancer. 2021;68(7):e28998doi: 10.1002/pbc.28998.
Alvarez, E., Malogolowkin, M., Pollock, B. H., Li, Q., Johnston, E., Marina, N., Wun, T., Thorpe, S., & Keegan, T. (2021). Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma-A population-based study. Pediatric blood & cancer, 68(7), e28998. https://doi.org/10.1002/pbc.28998
Alvarez, Elysia, et al. "Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma-A population-based study." Pediatric blood & cancer vol. 68,7 (2021): e28998. doi: https://doi.org/10.1002/pbc.28998
Alvarez E, Malogolowkin M, Pollock BH, Li Q, Johnston E, Marina N, Wun T, Thorpe S, Keegan T. Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma-A population-based study. Pediatr Blood Cancer. 2021 Jul;68(7):e28998. doi: 10.1002/pbc.28998. Epub 2021 Mar 15. PMID: 33720485.
Copy Download .nbib Format: NLM
Share it on

Pediatr Blood Cancer. 2021 Jul;68(7):e28998. doi: 10.1002/pbc.28998. Epub 2021 Mar 15.

Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma-A population-based study.

Pediatric blood & cancer

Elysia Alvarez, Marcio Malogolowkin, Brad H Pollock, Qian Li, Emily Johnston, Neyssa Marina, Ted Wun, Steven Thorpe, Theresa Keegan

Affiliations

  1. Division of Pediatric Hematology/Oncology, University of California Davis School of Medicine, Sacramento, California, USA.
  2. Department of Public Health Sciences, University of California Davis School of Medicine, Sacramento, California, USA.
  3. Center for Oncology Hematology Outcomes Research and Training and Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, California, USA.
  4. Division of Pediatric Hematology/Oncology and Institute of Cancer Outcomes and Survivorship, University of Alabama-Birmingham, Birmingham, Alabama, USA.
  5. Stanford University School of Medicine, Palo Alto, California, USA.
  6. Sarcoma Services, University of California Davis School of Medicine, Sacramento, California, USA.

PMID: 33720485 DOI: 10.1002/pbc.28998

Abstract

BACKGROUND: Ewing sarcoma (EWS) and osteosarcoma (OS) require multidisciplinary treatment. Care at specialized cancer centers (SCC: Children's Oncology Group affiliated and/or National Cancer Institute-designated cancer center) has been found to improve outcomes in patients with leukemia, but studies have not considered location of care and outcomes in EWS and OS patients, an ideal group to evaluate given their specialized multidisciplinary treatment needs.

METHODS: Patients hospitalized with primary EWS and OS (2000-2014) were identified using the California Cancer Registry linked with hospitalization data. Patients were divided into age groups (0-18, 19-39, ≥40 years), and classified on whether they received all versus part/none of their inpatient treatment at a SCC within 1 year of diagnosis. Multivariable Cox proportional hazards regression identified factors associated with survival.

RESULTS: There were 531 ES and 959 OS patients. Five-year overall survival was better for patients with EWS (all: 63% vs. part/none: 42%) and OS (all: 64% vs. part/none: 47%) who received all of their treatment at a SCC. After adjusting for sociodemographic and clinical factors, receiving all inpatient cancer treatment at a SCC was associated with superior overall survival (EWS HR: 0.49, CI 0.37-0.67; OS HR: 0.78, CI 0.63-0.97).

CONCLUSION: Our results suggest that treatment for EWS and OS at a SCC is associated with significantly improved survival even after adjustment for known prognostic factors. The superior survival among those treated at SCCs may be due to having greater access to clinical trials and services at SCCs.

© 2021 Wiley Periodicals LLC.

Keywords: Ewing sarcoma; adolescent and young adult; location of care; osteosarcoma

References

  1. Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015;39:189-195. - PubMed
  2. Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523-532. - PubMed
  3. Reed DR, Naghavi A, Binitie O. Sarcoma as a model for adolescent and young adult care. J Oncol Pract. 2019;15:239-247. - PubMed
  4. Wolfson J, Sun CL, Wyatt L, et al. Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: impact of care at specialized cancer centers on survival outcome. Cancer Epidemiol Biomarkers Prev. 2017;26:312-320. - PubMed
  5. Alvarez EM, Malogolowkin M, Li Q, et al. Decreased early mortality in young adult patients with acute lymphoblastic leukemia treated at specialized cancer centers in California. J Oncol Pract. 2019;15(4):e316-e327. - PubMed
  6. Muffly L, Alvarez E, Lichtensztajn D, et al. Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study. Blood Adv. 2018;2:895-903. - PubMed
  7. Wolfson JA, Sun CL, Wyatt LP, et al. Impact of care at comprehensive cancer centers on outcome: results from a population-based study. Cancer. 2015;121:3885-3893. - PubMed
  8. Paulson EC, Mitra N, Sonnad S, et al. National Cancer Institute designation predicts improved outcomes in colorectal cancer surgery. Ann Surg. 2008;248:675-686. - PubMed
  9. Onega T, Duell EJ, Shi X, et al. Influence of NCI cancer center attendance on mortality in lung, breast, colorectal, and prostate cancer patients. Med Care Res Rev. 2009;66:542-560. - PubMed
  10. Lee J, Hoang BH, Ziogas A, et al. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer. 2010;116:1964-1973. - PubMed
  11. Maretty-Nielsen K, Aggerholm-Pedersen N, Safwat A, et al. Prevalence and prognostic impact of comorbidity in soft tissue sarcoma: a population-based cohort study. Acta Oncol. 2014;53:1188-1196. - PubMed
  12. Alvarez E, Keegan T, Johnston EE, et al. Adolescent and young adult oncology patients: disparities in access to specialized cancer centers. Cancer. 2017;123:2516-2523. - PubMed
  13. Yost K, Perkins C, Cohen R, et al. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12:703-711. - PubMed
  14. Rosenberg AR, Kroon L, Chen L, et al. Insurance status and risk of cancer mortality among adolescents and young adults. Cancer. 2015;121:1279-1286. - PubMed
  15. Keegan THM, Parsons HM, Chen Y, et al. Impact of health insurance on stage at cancer diagnosis among adolescent and young adults. J Natl Cancer Inst. 2019;111(11):1152-1160. - PubMed
  16. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27. - PubMed
  17. Rodriguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer. 2007;110:375-384. - PubMed
  18. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30:4148-4154. - PubMed
  19. Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17:1396-1408. - PubMed
  20. Tsuda Y, Ogura K, Shinoda Y, et al. The outcomes and prognostic factors in patients with osteosarcoma according to age: a Japanese nationwide study with focusing on the age differences. BMC Cancer. 2018;18:614. - PubMed
  21. Jeon DG, Lee SY, Cho WH, et al. Primary osteosarcoma in patients older than 40 years of age. J Korean Med Sci. 2006;21:715-718. - PubMed
  22. Karski EE, McIlvaine E, Segal MR, et al. Identification of discrete prognostic groups in Ewing sarcoma. Pediatr Blood Cancer. 2016;63:47-53. - PubMed
  23. Baldini EH, Demetri GD, Fletcher CD, et al. Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg. 1999;230:79-86. - PubMed
  24. Karski EE, Matthay KK, Neuhaus JM, et al. Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol. 2013;37:29-33. - PubMed
  25. Koohbanani B, Han G, Reed D, et al. Ethnicity and age disparities in Ewing sarcoma outcome. Fetal Pediatr Pathol. 2013;32:246-252. - PubMed
  26. Esiashvili N, Goodman M. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol. 2008;30:425-430. - PubMed
  27. Verrill MW, Judson IR, Wiltshaw E, et al. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. Ann Oncol. 1997;8:1099-1105. - PubMed
  28. Gupta AA, Pappo A, Saunders N, et al. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer. 2010;116:3189-3194. - PubMed

Publication Types

Grant support